IDEXX Labs downgraded by BofA Securities with a new price target

5/5/22 6:20:45 AM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

BofA Securities downgraded IDEXX Labs from Buy to Neutral and set a new price target of $470.00 from $550.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IDXX

Date	Price Target	Rating	Analyst
12/2/2024	$500.00	Outperform	Leerink Partners
7/25/2024	$580.00	Buy	BTIG Research
1/30/2024	$525.00	Overweight → Neutral	Piper Sandler
12/7/2023	$602.00	Outperform	Exane BNP Paribas
12/4/2023		Neutral → Buy	Cleveland Research
8/2/2023	$610.00	Overweight → Neutral	Atlantic Equities
7/25/2022	$415.00	Buy → Hold	Stifel
7/21/2022	$530.00 → $435.00	Neutral → Buy	Goldman